Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Southern California
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVE:
I. To estimate the sensitivity and specificity of the fluid biopsy in establishing a diagnosis of bronchogenic carcinoma.
SECONDARY OBJECTIVES:
I. To determine the accuracy of determination of the histologic subtype of bronchogenic lung cancer.
II. To determine the relative contribution of cell based high definition circulating tumor cell assay (HD-CTC) and imaging mass cytometry (IMC) and plasma based circulating tumor deoxyribonucleic acid (ctDNA) assays in determination of diagnosis and histologic subtype.
OUTLINE:
Patients undergo collection of blood samples on day 1 for analysis via high definition (HD)-single cell analysis (SCA) fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or computed tomography (CT) screening.
After completion of study, patients are followed for up to 1 year.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Scheduled to undergo a diagnostic biopsy for possible lung cancer or
Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or
Planning or completed in the last 2 weeks a CT lung cancer screen
Ability to understand and the willingness to sign a written informed consent
You may not be if
Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment
Clareo Health | Fluid Biopsy for the Diagnosis of Lung Cancer
